Results from five Swedish randomized trials may provide the most conclusive evidence on the effect of mammographic screening and have been used to forecast the expected reduction in breast cancer mortality in other programs.
However, those trials demonstrated different degrees of reduction.
The interpretation of observed mortality reduction after long follow-up for women aged 40-49 years at trial entry is both important and controversial.
We estimated what percentage of the observed mortality reduction for women aged 40-49 years at entry into the five Swedish screening trials might be attributable to screening these women at 50 years of age or older.
An expected 7% reduction in breast cancer mortality for women aged 40-49 years at trial entry (relative risk [RR]=0.93) was determined by computer modeling, assuming no improvement in prognosis for cancers that are screen detected before 50 years of age.
Results from the Swedish randomized breast cancer-screening trials should be seen as more favorable regarding the effect of mammographic screening in reducing breast cancer mortality for women aged 50-69 years than was estimated earlier.
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Diagnostic, Stade précoce, Mortalité, Réduction, Analyse statistique, Interprétation information, Méthodologie, Suède, Europe, Homme, Femelle, Dépistage, Glande mammaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Diagnosis, Early stage, Mortality, Reduction, Statistical analysis, Information interpretation, Methodology, Sweden, Europe, Human, Female, Medical screening, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0570282
Code Inist : 002B20E02. Création : 01/03/1996.